Transthyretin Amyloid Cardiomyopathy Clinical Trial
TEGSEDI Pregnancy Surveillance Program
Summary
This is a worldwide safety surveillance study of pregnancy outcomes in women with hATTR-PN who may have been exposed or were not exposed to TEGSEDI prior to or during the pregnancy and of pediatric outcomes up to 1 year of age.
Eligibility Criteria
Inclusion Criteria:
TEGSEDI exposed patients (Cohort 1) meeting the following criteria will be eligible for study entry:
Pregnancies exposed to at least 1 dose of TEGSEDI within 25 weeks prior to conception or during pregnancy.
Able and willing to provide informed consent.
Unexposed patients (Cohort 2) meeting the following criteria will be eligible for study entry:
Have a diagnosis of hATTR-PN during pregnancy.
Have not been exposed to TEGSEDI within 25 weeks prior to conception or during pregnancy.
Able and willing to provide informed consent.
Exclusion Criteria:
None
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?